Skip to main content

Liver Injury, Drug Induced clinical trials at University of California Health

1 in progress, 0 open to eligible people

Showing trials for
  • MiroliverELAP® for the Treatment of Acute Liver Failure: a Phase 1 Trial

    Sorry, not currently recruiting here

    The clinical trail will assess the safety of miroliverELAP for the treatment of acute liver failure without underlying chronic liver disease. miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver graft and an extracorporeal blood circuit. miroliverELAP Is intended to support the native (failed) liver for up to 48-hours of continuous treatment to allow time for liver recovery or to identify a transplantable liver.

    at UCSF

Last updated: